Research Repository

Fas-threshold Signalling in MSCs Promotes Pancreatic Cancer Progression and Metastasis

Mohr, Andrea and Chu, Tianyuan and Clarkson, Christopher and Brooke, Greg and Teif, Vladimir and Zwacka, Ralf (2021) 'Fas-threshold Signalling in MSCs Promotes Pancreatic Cancer Progression and Metastasis.' Cancer Letters, 519. pp. 63-77. ISSN 0304-3835

Cancer Letters_Mohr et al._2021.pdf - Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (1MB) | Preview


Mesenchymal stem cells (MSCs) belong to the tumour microenvironment and have been implicated in tumour progression. We found that the number of MSCs significantly increased in tumour-burdened mice driven by Fas-threshold signalling. Consequently, MSCs lacking Fas lost their ability to induce metastasis development in a pancreatic cancer model. Mixing of MSCs with pancreatic cancer cells led to sustained production of the pro-metastatic cytokines CCL2 and IL6 by the stem cells. The levels of these cytokines were dependent on the number of MSCs, linking Fas-mediated MSC-proliferation to their capacity to promote tumour progression. Furthermore, we discovered that CCL2 and IL6 were induced by pancreatic cancer cell-derived IL1. Evidently, analysis of patient transcriptomic data revealed that high FasL expression correlates with high levels of MSC markers as well as increased IL6 and CCL2 levels in pancreatic tumours. Moreover, both FasL and CCL2 are linked to elevated levels of markers specific for monocytes known to possess further pro-metastatic activities. These results confirm our experimental findings of a FasL-MSC-IL1-CCL2/IL6 axis in pancreatic cancer and highlights the role of MSCs in tumour progression.

Item Type: Article
Uncontrolled Keywords: MSC-Proliferation; Pancreatic cancer; FasL; CCL2; IL1
Divisions: Faculty of Science and Health
Faculty of Science and Health > Life Sciences, School of
SWORD Depositor: Elements
Depositing User: Elements
Date Deposited: 29 Jun 2021 11:58
Last Modified: 18 Aug 2022 12:22

Actions (login required)

View Item View Item